ImmunityBio, a biotechnology company, has announced its financial results for the first quarter of the year.

ImmunityBio (IBRX) has been issued a warning by the FDA, though investment firm BTIG has indicated it will maintain a positive stance on the company's prospects.

ImmunityBio Inc. (IBRX) has received a warning letter from the FDA regarding claims made in an advertisement for its cancer therapy.

ImmunityBio (IBRX) has announced that the NCCN Clinical Practice Guidelines have been updated to include ANKTIVA for the treatment of papillary-only non-muscle invasive bladder cancer (NMIBC).

ImmunityBio's stock has seen gains following the inclusion of a new Anktiva indication in the National Comprehensive Cancer Network (NCCN) guidelines.

H.C. Wainwright has increased its price target for ImmunityBio, Inc. (IBRX) to $15 from $10, maintaining a Buy rating on the company's shares.

ImmunityBio is preparing for its fourth-quarter 2026 earnings announcement, with a preview of the upcoming financial report.

ImmunityBio (IBRX) stock has surged significantly after its drug Anktiva propelled a 671% increase in revenue.

ImmunityBio has established an Irish unit and secured a distribution agreement to enhance the availability of its drug Anktiva in Europe.

ImmunityBio's stock surged following the EU's approval of ANKTIVA for bladder cancer treatment.

ImmunityBio stock slumped on Monday, with the article exploring the reasons behind its decline.

ImmunityBio (IBRX) shares rallied 15% following the firm's announcement that it has raised $100 million to fund its global expansion initiatives.

ImmunityBio has successfully secured $75 million in financing as part of a deal with Oberland Capital.

Palantir's stock fell by 5% as the broader tech sector experienced a sell-off, raising questions about whether the company is being unfairly penalized.

Financial commentator Jim Cramer has expressed skepticism about ImmunityBio, stating that its stock is indicative of a 'magical thinking era' in the market.

ImmunityBio (IBRX) shares fell by 17% due to profit-taking after reaching an intra-day high.

ImmunityBio's stock experienced a significant surge today, with reasons for the increase being explored.

ImmunityBio (IBRX) stock soared to a new high, driven by optimism surrounding the future expansion of its drug Anktiva.

ImmunityBio's stock experiences a significant surge, attracting investor attention.

Investors in ImmunityBio, Inc. (IBRX) are being presented with an opportunity to lead a securities fraud class action lawsuit against the company.

Jim Cramer recommended owning ImmunityBio stock, with the caveat that investors should not own any other speculative stocks alongside it.

ImmunityBio's stock declined after the FDA issued a warning regarding an advertisement and podcast related to its drug Anktiva.

BTIG analysts are projecting an upside for ImmunityBio, Inc. (IBRX), attributing their positive outlook to strong anticipated sales growth for ANKTIVA in 2026.

ImmunityBio (IBRX) announced a significant 700% increase in revenue, primarily attributed to the rapid adoption of its product, ANKTIVA.

ImmunityBio announced its GAAP earnings per share of -$0.06 and reported revenue of $38.2 million for the latest quarter.

ImmunityBio is conducting a clinical trial for a lymphoma drug, following a significant $505 million convertible note change.

ImmunityBio's stock saw an increase after its bladder cancer therapy received approval in the European Union.